FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382810833> ?p ?o ?g. }

• W4382810833 endingPage "S22" @default.
• W4382810833 startingPage "S21" @default.
• W4382810833 abstract "The triplet combination of encorafenib, cetuximab, plus binimetinib (BEACON triplet regimen) showed survival benefit and a higher response over standard chemotherapy in pretreated patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) in the BEACON CRC study. The BEACON triplet regimen as well as encorafenib plus cetuximab are approved in previously treated patients with BRAF V600E-mutant mCRC in Japan, but with a limited number of Japanese patients treated with the BEACON triplet regimen. An expanded access program (EAP) was prospectively conducted to evaluate efficacy and safety of the BEACON triplet regimen for Japanese patients (JapicCTI-205146). Since it was inadequate to evaluate efficacy parameters including overall survival (OS) due to a median follow-up period in the EAP being only 4.6 months (range: 0.3–10.7), we herein conducted an additional study to evaluate efficacy parameters. The multicenter study retrospectively collected data from the medical record of patients treated with a BEACON triplet regimen who were confirmed alive at the end of the EAP. The study collected patient data from the day after the end of the EAP to December 31, 2021. Key eligibility were patients with BRAF V600E-mutant mCRC who progressed after one or two prior systemic chemotherapy. The primary endpoint was OS, and the secondary endpoints included best overall response (BOR) and progression-free survival (PFS). A total of 81 patients who received the BEACON triplet regimen in the EAP were enrolled from 10 Japanese institutions between Feb and Dec 2020. Of these, 58 patients were alive at the end of the EAP, and 57 patients were included in the follow-up study. The median age was 60 years (range: 20–82). Fifty-four patients (67%) had ECOG PS of 0. The median follow-up was 9.17 months (range: 0.3–22.1). The median duration of treatment with encorafenib, binimetinib, and cetuximab was 4.57 months (range: 0.1–17.8), 3.68 months (range 0.1–16.2), and 4.63 months (range: 0.2–17.7), respectively. The median OS was 10.38 months (95% confidence interval [CI]: 9.00–16.16) and the median PFS was 5.29 months (95%CI: 4.21–5.75). The confirmed ORR was 31.6% (95%CI: 21.4–43.3). Of the 81 patients, 40 patients (49.4%) received subsequent treatment: 2 (2.5%) with surgery, 3 (3.7%) with radiotherapy, and 39 (48.1%) with systemic chemotherapy. As systemic chemotherapy, trifluridine/tipiracil + bevacizumab (16 patients [19.8%]) was used most frequently. The clinical outcomes of the BEACON triplet regimen in the Japanese patients with BRAF V600E-mutant mCRC were consistent with those in the BEACON CRC study. These results support that the BEACON triplet regimen is one of the standard treatment for pretreated Japanese patients with BRAF V600E-mutant mCRC." @default.
• W4382810833 created "2023-07-02" @default.
• W4382810833 creator A5001214587 @default.
• W4382810833 creator A5002431268 @default.
• W4382810833 creator A5011207501 @default.
• W4382810833 creator A5015711180 @default.
• W4382810833 creator A5017987162 @default.
• W4382810833 creator A5023430800 @default.
• W4382810833 creator A5035264520 @default.
• W4382810833 creator A5043738572 @default.
• W4382810833 creator A5051218231 @default.
• W4382810833 creator A5053709496 @default.
• W4382810833 creator A5054182211 @default.
• W4382810833 creator A5054543898 @default.
• W4382810833 creator A5055212193 @default.
• W4382810833 creator A5058084087 @default.
• W4382810833 creator A5058524907 @default.
• W4382810833 creator A5062748030 @default.
• W4382810833 creator A5067881155 @default.
• W4382810833 date "2023-06-01" @default.
• W4382810833 modified "2023-10-16" @default.
• W4382810833 title "P-23 Clinical outcomes of encorafenib, binimetinib, and cetuximab for pretreated BRAF V600E-mutant metastatic colorectal cancer in the BEACON EAP follow-up study" @default.
• W4382810833 doi "https://doi.org/10.1016/j.annonc.2023.04.079" @default.
• W4382810833 hasPublicationYear "2023" @default.
• W4382810833 type Work @default.
• W4382810833 citedByCount "0" @default.
• W4382810833 crossrefType "journal-article" @default.
• W4382810833 hasAuthorship W4382810833A5001214587 @default.
• W4382810833 hasAuthorship W4382810833A5002431268 @default.
• W4382810833 hasAuthorship W4382810833A5011207501 @default.
• W4382810833 hasAuthorship W4382810833A5015711180 @default.
• W4382810833 hasAuthorship W4382810833A5017987162 @default.
• W4382810833 hasAuthorship W4382810833A5023430800 @default.
• W4382810833 hasAuthorship W4382810833A5035264520 @default.
• W4382810833 hasAuthorship W4382810833A5043738572 @default.
• W4382810833 hasAuthorship W4382810833A5051218231 @default.
• W4382810833 hasAuthorship W4382810833A5053709496 @default.
• W4382810833 hasAuthorship W4382810833A5054182211 @default.
• W4382810833 hasAuthorship W4382810833A5054543898 @default.
• W4382810833 hasAuthorship W4382810833A5055212193 @default.
• W4382810833 hasAuthorship W4382810833A5058084087 @default.
• W4382810833 hasAuthorship W4382810833A5058524907 @default.
• W4382810833 hasAuthorship W4382810833A5062748030 @default.
• W4382810833 hasAuthorship W4382810833A5067881155 @default.
• W4382810833 hasBestOaLocation W43828108331 @default.
• W4382810833 hasConcept C104317684 @default.
• W4382810833 hasConcept C121608353 @default.
• W4382810833 hasConcept C126322002 @default.
• W4382810833 hasConcept C143065580 @default.
• W4382810833 hasConcept C143998085 @default.
• W4382810833 hasConcept C185592680 @default.
• W4382810833 hasConcept C203092338 @default.
• W4382810833 hasConcept C2775832928 @default.
• W4382810833 hasConcept C2776470698 @default.
• W4382810833 hasConcept C2776694085 @default.
• W4382810833 hasConcept C2778336483 @default.
• W4382810833 hasConcept C2779998722 @default.
• W4382810833 hasConcept C2780739268 @default.
• W4382810833 hasConcept C2781413609 @default.
• W4382810833 hasConcept C526805850 @default.
• W4382810833 hasConcept C535046627 @default.
• W4382810833 hasConcept C55493867 @default.
• W4382810833 hasConcept C71924100 @default.
• W4382810833 hasConceptScore W4382810833C104317684 @default.
• W4382810833 hasConceptScore W4382810833C121608353 @default.
• W4382810833 hasConceptScore W4382810833C126322002 @default.
• W4382810833 hasConceptScore W4382810833C143065580 @default.
• W4382810833 hasConceptScore W4382810833C143998085 @default.
• W4382810833 hasConceptScore W4382810833C185592680 @default.
• W4382810833 hasConceptScore W4382810833C203092338 @default.
• W4382810833 hasConceptScore W4382810833C2775832928 @default.
• W4382810833 hasConceptScore W4382810833C2776470698 @default.
• W4382810833 hasConceptScore W4382810833C2776694085 @default.
• W4382810833 hasConceptScore W4382810833C2778336483 @default.
• W4382810833 hasConceptScore W4382810833C2779998722 @default.
• W4382810833 hasConceptScore W4382810833C2780739268 @default.
• W4382810833 hasConceptScore W4382810833C2781413609 @default.
• W4382810833 hasConceptScore W4382810833C526805850 @default.
• W4382810833 hasConceptScore W4382810833C535046627 @default.
• W4382810833 hasConceptScore W4382810833C55493867 @default.
• W4382810833 hasConceptScore W4382810833C71924100 @default.
• W4382810833 hasLocation W43828108331 @default.
• W4382810833 hasOpenAccess W4382810833 @default.
• W4382810833 hasPrimaryLocation W43828108331 @default.
• W4382810833 hasRelatedWork W1908989187 @default.
• W4382810833 hasRelatedWork W1963973664 @default.
• W4382810833 hasRelatedWork W1971638713 @default.
• W4382810833 hasRelatedWork W2120490763 @default.
• W4382810833 hasRelatedWork W2373916950 @default.
• W4382810833 hasRelatedWork W2729289325 @default.
• W4382810833 hasRelatedWork W2978084232 @default.
• W4382810833 hasRelatedWork W3026015583 @default.
• W4382810833 hasRelatedWork W4285392539 @default.
• W4382810833 hasRelatedWork W4292087709 @default.
• W4382810833 hasVolume "34" @default.
• W4382810833 isParatext "false" @default.
• W4382810833 isRetracted "false" @default.
• W4382810833 workType "article" @default.